Searched for
NOVO NORDISK 2025 OUTLOOK
FMCG, healthcare in line for strong show in FY27: BrickworksIndia's consumer goods and healthcare sectors are poised for robust growth this fiscal year, driven by tax relief, increasing consumer spen...
Titan expects gold prices to stay elevated, volatile amid global tensionsTitan anticipates elevated and volatile gold prices due to global geopolitical tensions, impacting short-term jewellery demand. However, th...
Consumer & healthcare best placed most sectors stable, says BrickworkIndia's consumer goods and healthcare sectors are poised for strong growth this fiscal year, fueled by tax cuts, rising consumer demand, an...
Microsoft launches firm to help companies adopt AI with $2.5 billionMicrosoft has launched a new venture, Microsoft Frontier Company, backed by $2.5 billion, to guide businesses in selecting and integrating ...
Medical device maker Zimmer Biomet to hire 500 employees in 3 years for tech centre in IndiaMedical device giant Zimmer Biomet is set to significantly expand its Indian footprint by hiring 500 professionals over three years for its...
Shantha Biologics to Make Injectable Drug Cartridges for Novo NordiskShantha Biologics has secured a significant contract with Danish pharmaceutical giant Novo Nordisk to manufacture cartridges for injectable...
Growth engine revving as GST, auto sales rise despite global roadblocksIndia's economy shows robust growth in Q1 FY27, with GST collections soaring 13.9% to Rs 1.95 lakh crore in June. Car sales surged 24%, and...
Solvency buffers at insurers thinning; general insurance sector more of a concernThe Reserve Bank of India's latest report highlights concerns over thinning capital in the insurance sector. While life insurers remain com...
Oyo parent files updated DRHP for Rs 6,650 crore IPO: Key things to knowOyo's parent company, Prism, has filed for a Rs 6,650 crore IPO, with plans for a potential pre-IPO placement. The bulk of the funds will b...
Oyo parent Prism files updated IPO papers for fresh issue worth Rs 6,650 croreOYO parent Prism, formerly Oravel Stays, has filed an updated DRHP with SEBI for a Rs 6,650 crore IPO entirely through fresh issue. Proceed...
PRISM files IPO papers for Rs 6650 crore fresh issue, reports Rs 748 crore profit in 9MFY26Oyo's parent company, PRISM, has filed its IPO papers with SEBI, planning a Rs 6,650 crore fresh issue to repay borrowings. The hospitality...
Waaree Energies shares crash 5%. Can this US ruling dent solar panel maker's image for long?Waaree Energies shares fell nearly 5% after a US Customs ruling triggered concerns over reputational impact despite the company’s clarifica...
Prestige Group holds Rs 65,000 crore unrecognised revenue in books on record pre-sales: Chairman Irfan RazackPrestige Estates Projects Ltd holds a substantial Rs 65,000 crore in unrecognised revenue, fueled by robust housing sales. The company repo...
India’s GLP-1 boom loses steam as price war, weak retention hit generic weight-loss drug salesInitial excitement for India's generic weight-loss drugs is fading. Domestic manufacturers are lowering sales targets due to slower-than-ex...
Healthium Medtech CEO Anish Bafna steps down, moves to non-executive chairman roleHealthium Medtech's CEO Anish Bafna is transitioning to non-executive chairman as KKR-owned company seeks a new chief within a month. Bafna...
Bombay HC cancels 'Duphachrit' trademark, rules it deceptively similar to Abbott's 'Dupha' familyThe Bombay High Court has cancelled Thane-based Menschlich Healthcare's trademark 'Duphachrit' in favour of Abbott Product Operations AG. T...
Kiran Mazumdar-Shaw eyes crown of world’s top insulin supplier for BioconIndian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...
UK approves Novo weight-loss pill to edge open European marketBritain's medicine regulator has approved Novo Nordisk's weight-loss pill. This makes the UK the first European market for the oral treatme...
Novo Nordisk hit by cyber incident, probes data breachDanish drugmaker Novo Nordisk has confirmed a security incident. Unauthorised access to internal IT systems occurred. Certain non-public da...
India’s anti-obesity drug market sees slower growth after initial surge in generic semaglutide salesIndia's anti-obesity drug market sees a slowdown after initial generic semaglutide sales. Demand has eased from its peak, with growth moder...